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The effect of the myo-inositol 1,4,5-trisphosphate (IP,) analogue, myo-inositol 1,4&trisphosphorothioate (IPS,) on the 
dephosphorylation of D-S-f2P]IP, by the 5-phosphatase from human erythrocyte membranes has been investigated. DL- 
IP& was found to act as a competitive inhibitor with a Ki of 6 pM, making it the most potent inhibitor currently available 
for this enzyme. LIP, inhibited the enzyme with a Ki of 124 gM and was more potent than D-2,3_diphosphoglycerate 
(Ki 978 PM). 
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1. INTRODUCTION 
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D-myo-Inositol 1,4,5-trisphosphate (DIPS) (1) 
is now established as the intracellular second 
messenger mediating calcium release from in- 
tracellular stores in stimulated cells [l]. D-IPs is 
metabolized via two pathways: an ATP-dependent 
phosphorylation to D-1,3,4,5-IP4 [2] and a 
5-phosphatase-catalyzed dephosphorylation to 
D-l ,4-IPz [3]. 5-Phosphatase was originally iden- 
tified in human erythrocyte membranes [4] and has 
subsequently been found in many different types 
of cell, including liver [5] and platelets, from which 
this enzyme has been purified to homogeneity [6]. 
Despite the obvious importance of this enzyme in 
deactivation of D-IPs and termination of the se- 
cond messenger response, no potent inhibitors of 
the 5-phosphatase are known, although 
D-2,3-diphosphoglycerate (2,3-DPG) was found to 
inhibit the enzyme relatively weakly with a Ki of 
350 PM [4]. 
We have recently introduced the novel IP3 
analogue DL-myo-inositol 1,4,5-trisphosphoro- 
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Fig. 1. Inositol derivatives tudied (single enantiomers hown): 
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thioate (IPS3) (2) [7], wherein the three phosphate 
groups have been replaced by phosphorothioate 
groups (fig.1) and which is a potent mobiliser of 
calcium [8,9] but is resistant o 5phosphatase [lo]. 
We reasoned that, since D-IPS3 is a good structural 
analogue of D-IP3, it might be expected to be an 
effective inhibitor of the 5phosphatase. We report 
here an investigation of this possibility. 
2. MATERIALS AND METHODS 
DL-IPr [11] and DL-IPSs [7] were synthesized as described. 
LIP3 was synthesized as for DL-IPr using the resolved precur- 
sor D-1,2,4-tri-0-benzyl-myo-inositol [12]. D-IP3 and 
D-5-[“P]IPr (100 ,&Zi/ml; 1000 Ci/mmol) were purchased 
from Amersham, England. 
Human erythrocyte ghosts were prepared according to 
Downes and Michell [13] and were stored at - 40°C and 2.6 mg 
protein/ml. The activity of 5-phosphatase was determined 
either by calorimetric monitoring of phosphate release from D- 
IPr using an inorganic phosphate assay or by using the 
specifically labelled substrate D-5-[32P]IPs and monitoring 
release of radioactivity in a similar fashion to Downes et al. [4]. 
Assay mixtures (50 PI), prepared in duplicate, in buffer (30 mM 
Hepes, 2 mM Mg2+ , pH 7.2), contained D-5-[32P]IP3 (0.33 nM, 
chosen to give -10000 dpm), DIP3 (30, 60 or 12OrM) and 
human erythrocyte ghost preparation (0.026 mg protein). In- 
cubations were performed at 37°C for 30 min, under which 
conditions no more than 20% of the substrate was consumed at 
a linear rate. For the competition experiments appropriate con- 
centrations of inhibitor were included in the mixtures. The 
release of 32P-inorganic phosphate was monitored as follows: 
mixtures were quickly diluted with 200 ~1 ice-cold buffer, quen- 
ched with 250 yl ice-cold HCl04 (2 M) and centrifuged at 16000 
x g for 5 min. 450 ~1 of the supernatant were taken and 50 /cl 
ammonium molybdate (100 mg/ml) were added. The complex- 
ed inorganic phosphate was separated from inositol phosphates 
by addition of isobutyl alcohol (400& and toluene (400pl). 
After vigorous mixing and phase separation by centrifugation, 
5001~1 of the upper layer were taken, added to 5 ml of scintilla- 
tion fluid (Optiphase X, LKB) and counted for radioactivity. 
The data were analysed by the method of Dixon (see Cornish- 
Bowden [15]). Kinetic data were computer fitted using standard 
linear regression techniques. 
Inorganic phosphate assays were carried out according to 
Moslen et al. [14]. Working colour reagent was freshly prepared 
daily. Thus, 10 ml ammonium molybdate (99.99%, Aldrich; 
4.2%, w/v, solution in 4.2 M HCl) and 30 ml malachite green 
hydrochloride (Sigma, 0.045070, w/v) were stirred together for 
20 min and filtered through Whatman 42 filter paper. Within 
1 h of assay 1.2 ml Tween 20 (Sigma, 1.5%, w/v) was added. 
Inorganic phosphate release from D-IPs was determined in in- 
cubations containing 200~1 D-IPs (50pM, in 30 mM 
Hepes/Z mM Mg 2+ buffer, pH 7.2) and 50~1 membrane 
preparation (0.13 mg protein) at 37°C. Reactions were ter- 
minated by boiling for 10 min. The samples were centrifuged at 
16000 x g for 5 min, 200 ~1 of the supernatant were taken and 
1.2 ml of the colour reagent was added. Samples were then in- 
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Fig.2. (a) Dixon plot for the determination of the Ki for 
phosphatase inhibition by D-2,3-diphosphoglycerate: Di- 
phosphoglycerate was added in various concentrations to 
5OfiM D-IPs spiked with 5-[32P]IPr (see section 2). The 
mixtures were then incubated with membrane preparation for 
30 min at 37°C. The reaction was quenched and the initial rate 
determined by counting the released radioactivity. (b) 
Eisenthal-Cornish-Bowden plot for the determination of the K,,, 
of IPr for 5-phosphatase: various concentrations of D-IPs 
spiked with 5-[32P]IP3 were incubated with membrane 
preparation for 30 min at 37°C. Dephosphorylation of IPs was 
monitored by counting the released 32P-inorganic phosphate. 
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cubated at, 37°C for 40 min and on cooling to ambient 
temperature the absorbance at 630 nm was measured within 
1 h. A standard curve was prepared for each assay by running 
blanks and a series of standards containing 0.5-10 nmol 
KH2P04 through the entire procedure. The assay is sensitive 
down to 0.3 nmol inorganic phosphate. 
3. RESULTS 
In our hands the K,,, and Vmax parameters for the 
human erythrocyte membrane 5phosphatase were 
40 pM and 1.1 nmol/min per mg protein, respec- 
tively (fig.2b; cf. 25 PM and 2.8 nmol/min per mg 
membrane protein, respectively [4]), and the Ki for 
D-2,3-DPG, the most potent inhibitor presently 
known, 978 pM (fig.2a; cf. 350,uM [4]). In con- 
trast, myo-inositol 1,4,5trisphosphorothioate 
(DL-IPSs), a non-hydrolysable analogue of the se- 
cond messenger D-myo-inositol 1,4,5_trisphos- 
phate (l), was a potent and competitive inhibitor 
of the enzyme with a Ki of 6 PM (fig.3). 
L-IP3 was a much weaker inhibitor of the 
5-phosphatase (Ki 124 PM: fig.4) and in our hands 
is not a substrate for the enzyme. Incubation of L- 
IPS with 5 times as much 5-phosphatase as used for 
the inhibition studies for long periods (up to 5 h) 
caused no detectable release of inorganic 
Fig.3. Dixon plot for the determination of the Ki for 
phosphatase inhibition by DL-IPS3. The effect of various 
concentrations of DL-IPSs on the rate of release of radioactive 
inorganic phosphate in mixtures containing various 
concentrations of DIP3 spiked with [32P]IPs after 30 min 
incubations at 37°C with 5-phosphatase was measured as 
described in section 2. 
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Fig.4. Dixon plot for the determination of the Ki for 
phosphatase inhibition by L-IPs: L-IPs was added in various 
concentrations to 50,uM D-IPs spiked with 5-[“P]IPs. The 
mixtures were incubated with 5-phosphatase for 30 min at 
37°C. The reaction was quenched and the initial rate 
determined by measuring release of radioactive inorganic 
phosphate. 
phosphate as measured by molybdate assay. Under 
identical conditions D-IP3 released its maximal 
amount of inorganic phosphate in approx. 1 h (not 
shown). 
4. DISCUSSION 
Myo-Inositol 1,4,5-trisphosphorothioate (2) was 
the first structural analogue of IP3 to be synthe- 
sized and is resistant to 5-phosphatase-catalyzed 
degradation. Although sulphur is somewhat larger 
than oxygen and the pKa values of phosphoro- 
thioates are slightly different from phosphates, 
phosphorothioates are generally expected to be 
well bound to biomolecules which recognize the 
natural substrate, and such analogues, especially 
those of nucleotides, have found considerable use 
as substrate analogues in mechanistic investiga- 
tions [ 161. Indeed, phosphorothioate analogues of 
another second messenger, CAMP, have recently 
been of great interest [16] and have been 
demonstrated to be both agonists and antagonists 
[17]. DL-IPS3 is recognized with high affinity by 
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intracellular sites mediating calcium release [8,9] 
and a specific DIP3 binding site in cerebellum 
[lo]. In both cases this analogue displayed only a 
slightly reduced affinity compared to the natural 
messenger. Thus, D-IPS3 might be expected to 
bind strongly to metabolic enzymes, such as 
5phosphatase or 3-kinase, but as a potentially 
poor substrate should act as a potent inhibitor. 
In our hands the membrane-bound 5-phospha- 
tase from human erythrocytes exhibited broadly 
similar values for the K,,, for D-IP3 and the Ki for 
D-2,3-DPG as previously reported [4]. DL-IPS3 
was found to be a potent competitive inhibitor of 
this enzyme possessing a Ki of 6/1M. It is of in- 
terest that this value is some 4-fold lower than the 
previously reported substrate K,,, for D-IP3 [4]. 
Despite the larger size of sulphur compared to ox- 
ygen, which might be expected to reduce the bin- 
ding affinity, the binding is obviously very tight. It 
is possible that at the pH used for these ex- 
periments (7.2) D-IPS3 is slightly more charged 
than D-IP3, due to the lower p& of the 
phosphorothioate group [18,19] and therefore 
more favourable interactions may be possible with 
the groups normally involved in phosphate binding 
at the active site. No pK, data are, however, yet 
available for either compound. Alternatively, the 
higher hydrophobicity of sulphur over oxygen may 
have a role to play in enhancing binding to the ac- 
tive site of 5phosphatase. 
Since the IX-II?% used was a racemic mixture it 
was necessary to establish whether the L- 
enantiomer (3) possessed inhibitory properties, or 
indeed was a substrate for the enzyme. The L- 
enantiomer of IP3 has already been shown to be 
very weak at binding to the D-IPS-specific 
cerebellum site [lo] and is very poor at releasing 
calcium [9]. In the present experiments, no 
breakdown of L-IP3 by 5phosphatase was discer- 
nable, but this enantiomer does inhibit the enzyme. 
The Ki of 124 /cM found for the L-isomer is clearly 
significantly lower than that for 2,3-DPG, where 
inhibition is most likely a function of the weak 
binding of a conformationally mobile vicinal 
bisphosphate moiety to a bisphosphate-binding 
site on the enzyme. L-IP3 (alternative name 
D-3,5,6-IP3) also possesses a vicinal bisphosphate 
but the presence of the inositol ring constrains the 
conformational mobility of the phosphate groups 
and they are fixed in an equatorial-equatorial rela- 
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tionship to each other in a similar fashion to the 
4,5-bisphosphate of D-IP3. It is therefore most 
likely that this extra rigidity is the factor primarily 
responsible for the approx. 8-fold lower Ki of L- 
IP3 compared to D-2,3-DPG. It does not seem like- 
ly that the L-l-phosphate group should have any 
appreciable role to play in binding interactions, 
although the possibility of an inverse binding mode 
to the D-IP3 site, where the three phosphates of an 
inverted L-IP3 occupy the phosphate binding sites 
for D-IP3 should not be excluded. 
In a Dixon plot for inhibition of an enzyme by 
a 50: 50 racemic mixture where each enantiomer 
has different inhibitory properties (inhibition con- 
stants Ki’ and Ki?) the plots for different substrate 
concentrations intersect at - 2K{K?/(Ki’ + Kt). 
Thus, using 124 pM, the measured Ki of L-IP3, as 
an upper limit for the putative Ki of L-IPS3, it is 
reasonable to presume that the contribution of the 
L-enantiomer to the overall inhibition measured 
will be small and a rough estimate of 3.1 ,uM for 
the Ki of D-IPS3 can be made. Although it has not 
been possible to estimate an accurate Ki for the D- 
enantiomer of IPS3, it is clear that even with an up- 
per limit for this value of 6 ,uM, DIPS3 will find 
use not only as a non-hydrolysable calcium 
mobilising analogue of D-IP3, but also as a potent 
inhibitor of 5-phosphatase. In view of the en- 
hanced metabolic stability of D-IPS3 its use when 
bound to an affinity chromatography support 
should open up new ways for purification of 
5-phosphatases and perhaps receptor sites linked 
to calcium release. 
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